Preclinical to clinical translation of tofacitinib, a janus kinase inhibitor, in rheumatoid arthritis

Journal of Pharmacology and Experimental Therapeutics

Volumn 348, Issue 1, 2014, Pages 165-173

  Dowty, Martin E ^a   Jesson, Michael I ^b   Ghosh, Sarbani ^c   Lee, Jamie ^b   Meyer, Debra M ^b   Krishnaswami, Sriram ^b   Kishore, Nandini ^c  

^a Pfizer Global Research and Development   (United States)

^b PFIZER INC   (United States)

^c Pfizer Worldwide Research and Development   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE RECEPTOR; HETERODIMER; JANUS KINASE 1; JANUS KINASE 2; JANUS KINASE INHIBITOR; TOFACITINIB;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; DISEASE ACTIVITY SCORE; DISEASE MODEL; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG EXPOSURE; DRUG POTENCY; DRUG RECEPTOR BINDING; MALE; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PREDICTION; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; STEADY STATE; TRANSLATIONAL RESEARCH; TREATMENT DURATION;

ANIMALS; ARTHRITIS, EXPERIMENTAL; DOUBLE-BLIND METHOD; DRUG EVALUATION, PRECLINICAL; HUMANS; JANUS KINASE 1; JANUS KINASE 3; MALE; MICE; MICE, INBRED DBA; PIPERIDINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; PYRROLES;

EID: 84891646211     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.113.209304     Document Type: Article

References (24)

1. Burmester GR, Blanco R, Charles-Schoeman C, Wollenhaupt J, Zerbini C, Benda B, Gruben D, Wallenstein G, Krishnaswami S, and Zwillich SH, et al.; ORAL Step investigators (2013) Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial. Lancet 381:451-460.
2. Changelian PS, Flanagan ME, Ball DJ, Kent CR, Magnuson KS, Martin WH, Rizzuti BJ, Sawyer PS, Perry BD, and Brissette WH, et al. (2003) Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor. Science 302:875-878.
3. Fleischmann R, Kremer J, Cush J, Schulze-Koops H, Connell CA, Bradley JD, Gruben D, Wallenstein GV, Zwillich SH, and Kanik KS; ORAL Solo Investigators (2012) Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med 367:495-507.
4. Fridman JS, Scherle PA, Collins R, Burn TC, Li Y, Li J, Covington MB, Thomas B, Collier P, and Favata MF, et al. (2010) Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050. J Immunol 184:5298-5307.
5. Ghoreschi K, Jesson MI, Li X, Lee JL, Ghosh S, Alsup JW, Warner JD, Tanaka M, Steward-Tharp SM, and Gadina M, et al. (2011) Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550). J Immunol 186:4234-4243.
6. Ghoreschi K, Laurence A, and O'Shea JJ (2009) Janus kinases in immune cell signaling. Immunol Rev 228:273-287.
7. Hutmacher MM, Krishnaswami S, and Kowalski KG (2008) Exposure-response modeling using latent variables for the efficacy of a JAK3 inhibitor administered to rheumatoid arthritis patients. J Pharmacokinet Pharmacodyn 35:139-157.
8. Ivashkiv LB and Hu X (2003) The JAK/STAT pathway in rheumatoid arthritis: pathogenic or protective? Arthritis Rheum 48:2092-2096.
9. Kremer J, Li ZG, Hall S, Fleischmann R, Genovese M, Martin-Mola E, Isaacs JD, Gruben D, Wallenstein G, and Krishnaswami S, et al. (2013) Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial. Ann Intern Med 159: 253-261.
10. LaBranche TP, Jesson MI, Radi ZA, Storer CE, Guzova JA, Bonar SL, Thompson JM, Happa FA, Stewart ZS, and Zhan Y, et al. (2012) JAK inhibition with tofacitinib suppresses arthritic joint structural damage through decreased RANKL production. Arthritis Rheum 64:3531-3542.
11. Lee EB, Fleischmann R, Hall S, van Vollenhoven RF, Bradley JD, Gruben D, Koncz T, Krishnaswami S, Wallenstein G, and Zwillich SH, et al.; ORAL Start investigators (2012) Radiographic, clinical and functional comparison of tofacitinib monotherapy versus methotrexate in methotrexate-naive patients with rheumatoid arthritis. Arthritis Rheum 64 (Suppl 10):S1049.
12. Lin TH, Hegen M, Quadros E, Nickerson-Nutter CL, Appell KC, Cole AG, Shao Y, Tam S, Ohlmeyer M, and Wang B, et al. (2010) Selective functional inhibition of JAK-3 is sufficient for efficacy in collagen-induced arthritis in mice. Arthritis Rheum 62:2283-2293.
13. Meyer DM, Jesson MI, Li X, Elrick MM, Funckes-Shippy CL, Warner JD, Gross CJ, Dowty ME, Ramaiah SK, and Hirsch JL, et al. (2010) Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis. J Inflamm (Lond) 7:41.
14. Milici AJ, Audoly L, Beckius GE, Gibbons CP, Perry BD, Fisher MB, Yoon K, Zwillich SH, and Changelian PS (2006) Cartilage preservation by inhibition of Janus kinase 3 (JAK3) in a murine collagen-induced-arthritis (CIA) model and rat adjuvantarthritis (AA) model. Arthritis Rheum 54:S353.
15. Milici AJ, Kudlacz EM, Audoly L, Zwillich S, and Changelian P (2008) Cartilage preservation by inhibition of Janus kinase 3 in two rodent models of rheumatoid arthritis. Arthritis Res Ther 10:R14.
16. Murray PJ (2007) The JAK-STAT signaling pathway: input and output integration. J Immunol 178:2623-2629.
17. O'Shea JJ (1997) Jaks, STATs, cytokine signal transduction, and immunoregulation: are we there yet? Immunity 7:1-11.
18. O'Shea JJ (2004) Targeting the Jak/STAT pathway for immunosuppression. Ann Rheum Dis 63 (Suppl 2):ii67-ii71.
19. Shuai K and Liu B (2003) Regulation of JAK-STAT signalling in the immune system. Nat Rev Immunol 3:900-911.
20. Suzuki M, Neelakantan S, Peterson M, Hutmacher M, and Krishnaswami S (2012) Dose response modeling of tofacitinib (CP-690,550) for the treatment of signs and symptoms of rheumatoid arthritis. Clin Pharmacol Ther 91: S76, abs PII-64.
21. van der Heijde D, Tanaka Y, Fleischmann R, Keystone E, Kremer J, Zerbini C, Cardiel MH, Cohen S, Nash P, and Song YW, et al.; ORAL Scan Investigators (2013) Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study. Arthritis Rheum 65:559-570.
22. van Vollenhoven RF, Fleischmann R, Cohen S, Lee EB, García Meijide JA, Wagner S, Forejtova S, Zwillich SH, Gruben D, and Koncz T, et al.; ORAL Standard Investigators (2012) Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med 367:508-519.
23. Walker JG and Smith MD (2005) The Jak-STAT pathway in rheumatoid arthritis. J Rheumatol 32:1650-1653.
24. Wang F, Sengupta TK, Zhong Z, and Ivashkiv LB (1995) Regulation of the balance of cytokine production and the signal transducer and activator of transcription (STAT) transcription factor activity by cytokines and inflammatory synovial fluids. J Exp Med 182:1825-1831.